{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:18:09Z","timestamp":1770574689517,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Correct identification of the fibrosis progression risk is a critical step in the management of patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), because liver fibrosis, especially advanced liver fibrosis, is difficult to reverse. However, the progression of liver fibrosis is typically unnoticeable, leading to many patients failing to adhere to long-term therapeutic interventions. Reliable clinical tools for the quantification of the fibrosis progression risk may have effects on following long-term therapeutic recommendations to avoid further liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to develop a nomogram for quantitatively estimating the risk of fibrosis progression in T2DM patients with NAFLD during lifestyle intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 432 medical records of T2DM patients with NAFLD were retrospectively analyzed in this study. We divided patients into the progression and no-progression groups according to whether the value of liver stiffness measurement (LSM) increased by &amp;gt; 2 kPa at the last visit. The independent factors associated with the fibrosis progression, which were screened by univariate and multivariate Logistic regression, constituted the nomogram to determine the likelihood of fibrosis progression in T2DM patients with NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-five of the 432 individuals (15%) were found to have fibrosis progression. Changes in body mass index [odds ratio (OR) = 1.586], glycosylated hemoglobin A1c (OR = 6.636), alanine aminotransferase (OR = 1.052), and platelet counts (OR = 0.908) were independently associated with fibrosis progression (all <jats:italic>P<\/jats:italic> &amp;lt; 0.05) and functioned as components of the newly developed nomogram. It showed satisfied discrimination and calibration after 1,000 bootstrapping. The DCA indicated that the nomogram yielded clinical net benefit when the threshold probability was &amp;lt; 0.8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a nomogram incorporating dynamic alterations in clinical features to estimate the risk of fibrosis progression in T2DM patients with NAFLD, which aids the patients\u2019 compliance with long-term life interventions while allowing for prompt intervention adjustments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.917304","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T05:28:21Z","timestamp":1656394101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Nomogram for Quantitatively Estimating the Risk of Fibrosis Progression in Type 2 Diabetic Patients With Nonalcoholic Fatty Liver Disease: A Pilot Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinying","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifeng","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762","article-title":"The Diagnosis and Management of non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32511-3","article-title":"Non-Alcoholic Fatty Liver Disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, But No Other Histologic Features, Is Associated With Long-Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis Stage But Not NASH Predicts Mortality and Time to Development of Severe Liver Disease in Biopsy-Proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085","article-title":"Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25772","article-title":"Association Between Diabetes, Family History of Diabetes, and Risk of Nonalcoholic Steatohepatitis and Fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i25.2610","article-title":"Histopathological Differences Utilizing the Nonalcoholic Fatty Liver Disease Activity Score Criteria in Diabetic (Type 2 Diabetes Mellitus) and non-Diabetic Patients With Nonalcoholic Fatty Liver Disease","volume":"7","author":"Puchakayala","year":"2015","journal-title":"World J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening Diabetic Patients for non-Alcoholic Fatty Liver Disease With Controlled Attenuation Parameter and Liver Stiffness Measurements: A Prospective Cohort Study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The Global Epidemiology of NAFLD and NASH in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.205088","article-title":"Disease Progression of non-Alcoholic Fatty Liver Disease: A Prospective Study With Paired Liver Biopsies at 3 Years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12651","article-title":"Adherence to Diabetes Medication: A Systematic Review","volume":"32","author":"Krass","year":"2015","journal-title":"Diabetes Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13637","article-title":"Management of Patients With non-Alcoholic Steatohepatitis (NASH) in Real Life","author":"Serfaty","year":"2018","journal-title":"Liver Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.031","article-title":"Stage of Change and Motivation to Healthier Lifestyle in non-Alcoholic Fatty Liver Disease","volume":"58","author":"Centis","year":"2013","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cld.2017.08.005","article-title":"Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"22","author":"Esterson","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease: Current Evidence and Practice","volume":"25","author":"Zhou","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.175","article-title":"Noninvasive Evaluation of NAFLD","volume":"10","author":"Castera","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4079-4","article-title":"Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016","volume":"61","author":"Kaswala","year":"2016","journal-title":"Dig Dis Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29302","article-title":"Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Meta-Analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221382","article-title":"Transient Elastography as a Screening Tool for Liver Fibrosis and Cirrhosis in a Community-Based Population Aged Over 45 Years","volume":"60","author":"Roulot","year":"2011","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-Invasive Assessment of non-Alcoholic Fatty Liver Disease: Clinical Prediction Rules and Blood-Based Biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142021","volume":"44","year":"2020","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and Prognostic Research: What, Why, and How","volume":"338","author":"Moons","year":"2009","journal-title":"Bmj"},{"key":"B30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31142","article-title":"Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study","volume":"72","author":"Lee","year":"2020","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000168641.31321.fa","article-title":"Weight Loss as a Treatment for Non-Alcoholic Fatty Liver Disease","volume":"1","author":"Clark","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00803-x","article-title":"Liraglutide Safety and Efficacy in Patients With Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326","article-title":"A Placebo-Controlled Trial of Pioglitazone in Subjects With Nonalcoholic Steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13480","article-title":"Serum Biomarkers Can Predict a Change in Liver Fibrosis 1 Year After Lifestyle Intervention for Biopsy-Proven NASH","volume":"37","author":"Vilar-Gomez","year":"2017","journal-title":"Liver Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04977.x","article-title":"How Should We Manage Patients With non-Alcoholic Fatty Liver Disease in 2007","volume":"22","author":"Chan","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477","article-title":"A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis With Fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61933-4","article-title":"Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for non-Cirrhotic, non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.917304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T05:28:24Z","timestamp":1656394104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.917304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":39,"alternative-id":["10.3389\/fendo.2022.917304"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.917304","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"article-number":"917304"}}